|
1
|
Marx RE: Pamidronate (Aredia) and
zoledronate (Zometa) induced avascular necrosis of the jaws: A
growing epidemic. J Oral Maxillofac Surg. 61:1115–1117. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ruggiero SL, Dodson TB, Fantasia J,
Goodday R, Aghaloo T, Mehrotra B and O'Ryan F; American Association
of Oral and Maxillofacial Surgeons: American association of oral
and maxillofacial surgeons position paper on medication-related
osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg.
72:1938–1956. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rupel K, Ottaviani G, Gobbo M, Contardo L,
Tirelli G and Vescovi P: DiL enarda R and Biasotto M: A systematic
review of therapeutical approaches in bisphosphonates-related
osteonecrosis of the jaw (BRONJ). Oral Oncol. 50:1049–1057. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fliefel R, Tröltzsch M, Kühnisch J,
Ehrenfeld M and Otto S: Treatment strategies and outcomes of
bisphosphonate-related osteonecrosis of the jaw (BRONJ) with
characterization of patients, A systematic review. Int J Oral
Maxillofac Surg. 44:568–585. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hayashida S, Uda A, Yamada S, Yanamoto S,
Kawasaki G, Kakehashi H, Asahina I and Umeda M: A study of
treatment for bisphosphonate-related osteonecrosis of the jaw
(BRONJ)-Indication and method of surgery in patients with stage II
BRONJ-J. Jpn Stomatol Soc. 64:18–27. 2015.
|
|
6
|
Weinstein RS, Roberson PK and Manolagas
SC: Giant osteoclast formation and long-term oral bisphosphonate
therapy. N Engl J Med. 360:53–62. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jain N and Weinstein RS: Giant osteoclasts
after long-term bisphosphonate therapy: Diagnostic challenges. Nat
Rev Rheumatol. 5:341–346. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cho YA, Yoon HJ, Lee JI, Hong SP and Hong
SD: Histopathological features of bisphosphonate-associated
osteonecrosis, Findings in patients treated with partial
mandibulectomies. Oral Surg Oral Med Oral Pathol Oral Radiol.
114:785–791. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Baron R, Ferrari S and Russell RG:
Denosumab and bisphosphonates, Different mechanisms of action and
effects. Bone. 48:677–692. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Taylor KH, Middlefell LS and Mizen KD:
Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J
Oral Maxillofac Surg. 48:221–223. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Aghaloo TL, Felsenfeld AL and Tetradis S:
Osteonecrosis of the jaw in a patient on denosumab. Br J Oral
Maxillofac Surg. 48:221–223. 2010.PubMed/NCBI
|
|
12
|
Malan J, Ettinger K, Naumann E and Beirne
OR: The relationship of denosumab pharmacology and osteonecrosis of
the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol. 114:671–676.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pichardo SE, Kuypers SC and van Merkesteyn
JP: Denosumab osteonecrosis of the mandible. A new entity? A case
report. J Craniomaxillofac Surg. 41:e65–e69. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Otto S, Baumann S, Ehrenfeld M and Pautke
C: Successful surgical management of osteonecrosis of the jaw due
to RANK-ligand inhibitor treatment using fluorescence guided bone
resection. J Craniomaxillofac Surg. 41:694–698. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Neuprez A, Coste S, Rompen E, Crielaard JM
and Reginster JY: Osteonecrosis of the jaw in a male osteoporotic
patient treated with denosumab. Osteoporos Int. 25:393–395. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Olate S, Uribe F, Martinez F, Almeida A
and Unibazo A: Osteonecrosis of the jaw in patient with denosumab
therapy. Int J Clin Exp Med. 7:3707–3709. 2014.PubMed/NCBI
|
|
17
|
O'Halloran M, Boyd NM and Smith A:
Denosumab and osteonecrosis of the jaws-the pharmacology,
pathogenesis and a report of two cases. Aust Dent J. 59:516–519.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Aghaloo TL, Dry SM, Mallya S and Tetradis
S: Stage 0 osteonecrosis of the jaw in a patient on denosumab. J
Oral Maxillofac Surg. 72:702–716. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Littlewood-Evans A, Kokubo T, Ishibashi O,
Inaoka T, Wlodarski B, Gallagher JA and Bilbe G: Localization of
cathepsin K in human osteoclasts by in situ hybridization and
immunohistochemistry. Bone. 20:81–86. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qi WX, Tang LN, He AN, Yao Y and Shen Z:
Risk of osteonecrosis of the jaw in cancer patients receiving
denosumab, A meta-analysis of seven randomized controlled trials.
Int J Clin Oncol. 19:403–410. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Scagliotti GV, Hirsh V, Siena S, Henry DH,
Woll PJ, Manegold C, Solal-Celigny P, Rodriguez G, Krzakowski M,
Mehta ND, et al: Overall survival improvement in patients with lung
cancer and bone metastases treated with denosumab versus zoledronic
acid: Subgroup analysis from a randomized phase 3 study. J Thorac
Oncol. 7:1823–1829. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fizazi K, Carducci M, Smith M, Damião R,
Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, et al:
Denosumab versus zoledronic acid for treatment of bone metastases
in men with castration-resistant prostate cancer: A randomised,
double-blind study. Lancet. 377:813–822. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Henry DH, Costa L, Goldwasser F, Hirsh V,
Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A,
Vadhan-Raj S, et al: Randomized, Double-blind study of denosumab
versus zoledronic acid in the treatment of bone metastases in
patients with advanced cancer (excluding breast and prostate
cancer) or multiple myeloma. J Clin Oncol. 29:1125–1132. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
McClung MR, Lewiecki EM, Cohen SB,
Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD,
Lederman SN, Chesnut CH, et al: Denosumab in postmenopausal women
with low bone mineral density. N Engl J Med. 354:821–831. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Miller PD, Bolognese MA, Lewiecki EM,
McClung MR, Ding B, Austin M, Liu Y and San Martin J: Amg Bone Loss
Study Group: Effect of denosumab on bone density and turnover in
postmenopausal women with low bone mass after long-term continued,
discontinued and restarting of therapy. A randomized blinded phase
2 clinical trial. Bone. 43:222–229. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pierroz DD, Bonnet N, Baldock PA, Ominsky
MS, Stolina M, Kostenuik PJ and Ferrari SL: Are osteoclasts needed
for the bone anabolic response to parathyroid hormone? A study of
intermittent parathyroid hormone with denosumab or alendronate in
knock-in mice expressing humanized RANKL. J Biol Chem.
285:28164–28173. 2010. View Article : Google Scholar : PubMed/NCBI
|
